Endoprosthesis for the treatment of type A aortic dissection

Original title: Application of Open Triple-Branch Aortic Arch Stent Graff for Acute Stanford Type A Aortic Dissection Reference: Fei Hua, et; al. Vascular Endovascular Surgery 47;2:109-14

Type A aortic dissection is a disease of high morbidity and mortality, especially in the early hours . Surgery is the treatment of choice but still have a significant complication rate .

We analyzed 34 patients with type A aortic dissection treated with branched stent for neck vessels ( Aortec Medical Technology Co Ltd , Beijing , China ) and were compared with 16 patients who underwent conventional surgery . No significant differences in baseline characteristics of both groups.

The procedure was performed under general anesthesia with median stereotomy, cardiopulmonary bypass , blood cardioplegia and deep hypothermia before implantation of the stent and its branches. The group that received stents had lower cardiopulmonary bypass time ( 186 ± 38 min . Versus 204 ± 47 min .), lower myocardial ischemic  time ( 101 ± 27 min . Versus 119 ± 30 min .) , shorter selective brain perfusion time ( 39 ± 11 min . Versus 46 ± 11 min . ) , as well as mechanical ventilation assistance  (19.9 ± 3.4 hours versus 20.4 ± 3.7 hours. ) And stay in intensive care (82.1 ± 11.2 hours. Versus  89.2 ± 13.1 hours.) During hospitalization 2 patients died, one required dialysis , 2 evolved with arm mobility impairments and one  presented consciousness disorders. At 9.6 months (2-24 months) follow-up , no patient died and only one had right arm motility difficulty  and required rehabilitation. Control tomography was performed in all patients witnessing a correct stent implantation with the preserved flow in the legs without significant leaks .

Conclusion:

This stent would be useful for those patients who require surgical reconstruction of the thoracic aorta , thus reducing the time of cardiopulmonary bypass from traditional surgery and potential complications thereof . 

Comment:

While this is a small population, indicates that it was possible to satisfactory solve, with this strategy favorably resolve such a complex disease , reducing surgical time and intensive areas and a good performance in the medium term. 

Courtesy by Dr Carlos Fava
Interventional Cardiologist
Favaloro Foundation
Buenos Aires – Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...